These findings demonstrate that FA suppresses hepatic lipid accumulation by targeting PGC-1β, suggesting that it could be a promising agent for the treatment or remission of MASLD. Here, PPARGC1B is linked to metabolic dysfunction-associated steatotic liver disease.